Atlas Trials

Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence

Clinical trial NCT05062096 · UNKNOWN

Trial details

NCT number
NCT05062096
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Melanoma
Start date
2022-11-01
Primary completion
2023-12-01
Enrollment
220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.